Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (MYOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,623,400
  • Shares Outstanding, K 97,235
  • Annual Sales, $ 230,970 K
  • Annual Income, $ -205,980 K
  • 60-Month Beta 2.17
  • Price/Sales 11.36
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MYOV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.91
  • Most Recent Earnings $-0.59 on 01/26/23
  • Next Earnings Date 01/25/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.46
  • Number of Estimates 1
  • High Estimate -0.46
  • Low Estimate -0.46
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +26.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.90 +0.30%
on 02/13/23
27.06 -0.30%
on 02/13/23
+0.08 (+0.30%)
since 02/09/23
3-Month
26.75 +0.86%
on 12/16/22
27.06 -0.30%
on 02/13/23
+0.19 (+0.71%)
since 12/09/22
52-Week
7.67 +251.76%
on 05/09/22
27.06 -0.30%
on 02/13/23
+14.66 (+118.99%)
since 03/09/22

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV). Such...

MYOV : 26.98 (-0.04%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV). Such...

MYOV : 26.98 (-0.04%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NYSE: MYOV). Such...

MYOV : 26.98 (-0.04%)
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MYOV : 26.98 (-0.04%)
PTN : 2.00 (+0.50%)
Myovant Sciences: Fiscal Q3 Earnings Snapshot

Myovant Sciences: Fiscal Q3 Earnings Snapshot

MYOV : 26.98 (-0.04%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, LBAI, FCRD, MYOV

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SAFE : 19.33 (+0.16%)
LBAI : 13.43 (+1.13%)
FCRD : 4.54 (-3.61%)
MYOV : 26.98 (-0.04%)
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Myovant Sciences (NYSE: MYOV) to Sumitomo Pharma...

MYOV : 26.98 (-0.04%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBAI, IMRA, MYOV, IAA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

LBAI : 13.43 (+1.13%)
IMRA : 6.32 (+15.96%)
MYOV : 26.98 (-0.04%)
IAA : 39.89 (-0.10%)
MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV

/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...

MYOV : 26.98 (-0.04%)
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences

/PRNewswire/ -- Shareholder rights law firm Julie & Holleman is investigating the proposed acquisition of Myovant Sciences (NYSE: MYOV) by affiliates of its...

MYOV : 26.98 (-0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral...

See More

Key Turning Points

3rd Resistance Point 27.01
2nd Resistance Point 27.01
1st Resistance Point 26.99
Last Price 26.98
1st Support Level 26.97
2nd Support Level 26.97
3rd Support Level 26.95

See More

52-Week High 27.06
Last Price 26.98
Fibonacci 61.8% 19.65
Fibonacci 50% 17.36
Fibonacci 38.2% 15.08
52-Week Low 7.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar